'Reagents + Instruments' | Bundled sales, but also to be cleared
Pharmaceutical Network November 8 hearing equipment bundling consumables sales are under strict management, and equipment bundling reagent sales, this path should not go well.
On November 6, Anhui Provincial Health Planning Commission released the Implementation Plan of Intensive Central Bank Transaction of Clinical Laboratory Reagents of Public Medical Institutions in Anhui Province (Draft for Soliciting Opinions) (hereinafter referred to as the Draft) for public comment.
Following the medical supplies and medical equipment, Anhui Province, but also on clinical testing reagents online centralized procurement.
The implementation scope is as follows: Public medical institutions, including grassroots level medical institutions, run by the government at all levels in the province, state-owned enterprises (including state-controlled enterprises).
In principle, the testing reagents commonly used in clinical testing projects of public medical institutions in Anhui Province are all included in the scope of centralized purchasing.
That is, either generic (open) test kits or dedicated (closed) test kits should be centrally procured and public health agencies at all levels are involved.
Procurement methods and high value supplies, the implementation of the province's unified network limit + medical institutions with the amount of procurement.
From other provinces in the price / Hanging limit the lowest price and Anhui Province, municipal public hospital The last actual purchase In the second lowest price of the price, take a low value as the limit price; if there is no other province product, the price will be reduced by 20% according to the median price of the hospital's last actual purchase price.
Then, the medical institutions and enterprises with the bargaining volume, to determine a not higher than the net price limit the actual purchase price.
High-value supplies, Anhui is the province is divided into three areas with the amount of procurement, do not know whether the reagent consumables approach, or reference drug The implementation of '16 +1 'with the amount of procurement methods.
In Vitro Diagnostic Reagents Provincial level net purchase, currently not many domestic provinces, such as Sichuan and Shanxi.
Regardless of Sichuan or Shanxi model, price cuts are the main appeal, Anhui is no exception.
Shanxi's net limit rules are exclusive or non-exclusive products, down more than 10% as a limit.Anhui Province recently made a special emergency notice, requiring enterprises to truthfully fill in the Guangxi price and Shanxi limit price.
Anhui should focus on reference to the Shanxi limit, combined with the proposed set of mining programs, the same product, Anhui will only be lower than the limit of Shanxi. After the limit there is a quantity with the purchase of bargain.
In vitro diagnostic reagents, Anhui price storm is coming!
It is noteworthy that in the "Draft", there is such an element:
'Clean up the sale of the bundled clinical laboratory reagents in the form of leasing, donation, delivery of equipment, etc. The price of online transaction of such clinical laboratory reagents should not be less than the average decrease of the clinical reagents purchased by the unit.'
'Instrumentation + Reagents' bundled sales, which is the most important sales model of the domestic IVD market, almost no IVD vendors do not do that, do not want to do so.
A well-known domestic IVD company, the original instrument more obvious advantages, this year, relying on 'instrumentation + reagents' bundling strategy, the company achieved rapid sales reagent sales, the overall revenue also increased steadily, the net profit margin is even more significant increase.
Some go past proxy Well-known instrument sales path enterprise , As well as well-known enterprises that mainly rely on diagnostic reagents, have also started to launch their own brand of closed-end testing instruments in an attempt to enhance their competitiveness and eliminate other products with the bundling strategy of "reagent + equipment".
IVD products have become more and more closed, the more closed the so-called sales model, profitability, which is favored by manufacturers, capital is also favored mode, but much criticism.
Once, Anhui "draft" in the clean up the New Deal introduced, many manufacturers should be to be hit.Can continue to bundle sales is one thing, the implementation of bundled sales reagent price decline is inevitable, you want to rely on closed Operational high prices to die.
In addition, not long ago, there was also an IVD company being asked by the SFC about whether its business model was lawful and legally binding, and whether it belonged to the act of leasing, donating or putting on equipment in the form of bundling sales by business agents.
'Instrument + Reagents' bundled sales model, has been the 'equipment + supplies' bundled mode of follow-up, has also been focused on.
This is a popular business model, but also a successful business model, however, the future path of this is not easy to go, this model will not be identified as commercial bribery, really hard to say now.
Medical reform and medical anti-corruption wind tight, the focus of medical supplies, special remediation has already begun, the field of in vitro diagnostics is far?
